StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc (VRTX) stock

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3030% above fair value
$534.20−3.59 (-0.67%)

Close on Nov 17, 2026Market cap $135.40BP/E 31.1Yield –

Earnings

Vertex Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 11, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$3.44B
Non-GAAP, Q3 FY2026
$4.76
Latest guidance
Issued
Nov 2, 2026 · 4 items

Quarterly results

Revenue and earnings per share from each of Vertex Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 11, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 2, 2026after the close$3.44B–$2.56$4.76Release
Q2 FY2026ended Jun 30, 2026Aug 3, 2026during market hours$3.33B+12.5%$4.31$4.73Release
Q1 FY2026ended Mar 31, 2026May 4, 2026during market hours$2.99B+7.8%$4.02$4.47Release
Q4 FY2025ended Dec 31, 2025Feb 12, 2026during market hours$3.19B+9.5%$4.65$5.03Release
Q3 FY2025ended Sep 30, 2025Nov 3, 2025during market hours––––Release
Q2 FY2025ended Jun 30, 2025Aug 4, 2025during market hours$2.96B+11.7%$3.99$4.52Release
Q1 FY2025ended Mar 31, 2025May 5, 2025during market hours$2.77B+3.0%$2.49$4.06Release
Q4 FY2024ended Dec 31, 2024Feb 10, 2025during market hours$2.91B+15.6%$3.50$3.98Release
Q3 FY2024ended Sep 30, 2024Nov 4, 2024during market hours$2.77B+11.7%$4.01$4.38Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024during market hours$2.65B+6.4%-$13.92-$12.83Release
Q1 FY2024ended Mar 31, 2024May 6, 2024during market hours$2.69B+13.5%$4.21$4.76Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Vertex Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total revenueFY2026$13.15B – $13.25B–NewNov 2, 2026
Total revenueFY2026$13.10B – $13.20B$12.95B – $13.10BRaisedAug 3, 2026
Combined GAAP R&D, AIPR&D and SG&A expensesGAAPFY2026$6.30B – $6.45B$6.30B – $6.45BReaffirmedAug 3, 2026
Combined GAAP R&D, AIPR&D, and SG&A expensesGAAPFY2026$7.15B – $7.20B–NewNov 2, 2026
Combined non-GAAP R&D, AIPR&D and SG&A expensesnon-GAAPFY2026$5.65B – $5.75B$5.65B – $5.75BReaffirmedAug 3, 2026
Combined non-GAAP R&D, AIPR&D, and SG&A expensesnon-GAAPFY2026$6.00B–NewNov 2, 2026
Non-CF product revenueFY2026$500.00M–NewMay 4, 2026
Non-GAAP effective tax ratenon-GAAPFY202619.5% – 20.5%–NewNov 2, 2026
Non-GAAP effective tax ratenon-GAAPFY202619.5% – 20.5%19.5% – 20.5%ReaffirmedAug 3, 2026

Guidance history

Every forecast Vertex Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 2, 2026Non-GAAP effective tax rateFY202619.5% – 20.5%New
Nov 2, 2026Combined GAAP R&D, AIPR&D, and SG&A expensesFY2026$7.15B – $7.20BNew
Nov 2, 2026Combined non-GAAP R&D, AIPR&D, and SG&A expensesFY2026$6.00BNew
Nov 2, 2026Total revenueFY2026$13.15B – $13.25BNew
Aug 3, 2026Combined GAAP R&D, AIPR&D and SG&A expensesFY2026$6.30B – $6.45BReaffirmed
Aug 3, 2026Non-GAAP effective tax rateFY202619.5% – 20.5%Reaffirmed
Aug 3, 2026Combined non-GAAP R&D, AIPR&D and SG&A expensesFY2026$5.65B – $5.75BReaffirmed
Aug 3, 2026Total revenueFY2026$13.10B – $13.20BRaised
Aug 3, 2026non-CF productsFY2026$500.00MLowered
May 4, 2026Non-CF product revenueFY2026$500.00MNew
May 4, 2026Non-GAAP effective tax rateFY202619.5% – 20.5%Reaffirmed
May 4, 2026Combined non-GAAP R&D, AIPR&D and SG&A expensesFY2026$5.65B – $5.75BReaffirmed
May 4, 2026Combined GAAP R&D, AIPR&D and SG&A expensesFY2026$6.30B – $6.45BReaffirmed
May 4, 2026Total revenueFY2026$12.95B – $13.10BRaised
Feb 12, 2026Non-GAAP effective tax rateFY202619.5% – 20.5%New
Feb 12, 2026Combined GAAP R&D, AIPR&D and SG&A expensesFY2026$6.30B – $6.45BNew
Feb 12, 2026Combined non-GAAP R&D, AIPR&D and SG&A expensesFY2026$5.65B – $5.75BNew
Feb 12, 2026Non-CF product revenueFY2026$500.00MLowered
Feb 12, 2026Total revenueFY2026$12.95B – $13.10BNew
Nov 3, 2025Total revenueFY2025$11.90B – $12.00BRaised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Adjusted figures

Non-GAAP numbers Vertex Pharmaceuticals reports itself, taken from its earnings releases

MeasureQ3 FY2026Q2 FY2026Q1 FY2026
Non-GAAP operating income$1.41B$1.42B$1.31B
Non-GAAP net income$1.20B$1.21B$1.15B
Non-GAAP$4.76$4.73$4.47

Read from the company's own earnings releases; hover a figure for the sentence it came from. Companies choose what to leave out of an adjusted number and there is no standard for it, so these are not comparable between companies the way the audited statements are. Margins here are computed from the adjusted revenue of the same period.

Press releases

Releases Vertex Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Results

See a number that looks wrong?